Swann Steven L, Song Danying, Sun Chaohong, Hajduk Philip J, Petros Andrew M
Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064.
ACS Med Chem Lett. 2010 Jun 24;1(6):295-9. doi: 10.1021/ml1000849. eCollection 2010 Sep 9.
NMR spectroscopy has enjoyed widespread success as a method for screening protein targets, especially in the area of fragment-based drug discovery. However, current methods for NMR-based screening all suffer certain limitations. Two-dimensional methods like "SAR by NMR" require isotopically labeled protein and are limited to proteins less than about 50 kDa. For one-dimensional, ligand-based methods, results can be confounded by nonspecific compound binding, resonance overlap, or the need for a special NMR probe. We present here a ligand-based method that relies on the exchange broadening observed for a (13)C-labeled molecule upon binding to a protein target (labeled ligand displacement). This method can be used to screen both individual compounds and mixtures and is free of the artifacts inherent in other ligand-based methods.
核磁共振光谱法作为一种筛选蛋白质靶点的方法已取得广泛成功,尤其是在基于片段的药物发现领域。然而,目前基于核磁共振的筛选方法都存在一定局限性。像“核磁共振波谱法的构效关系”这样的二维方法需要同位素标记的蛋白质,并且仅限于分子量小于约50 kDa的蛋白质。对于一维的基于配体的方法,结果可能会因非特异性化合物结合、共振重叠或对特殊核磁共振探针的需求而混淆。我们在此提出一种基于配体的方法,该方法依赖于观察到的(13)C标记分子与蛋白质靶点结合时的交换加宽现象(标记配体置换)。此方法可用于筛选单个化合物和混合物,且不存在其他基于配体的方法所固有的假象。